Revance Therapeutics (NASDAQ:RVNC) Now Covered by StockNews.com

StockNews.com began coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research note issued to investors on Wednesday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Other analysts have also issued reports about the company. Barclays lowered their target price on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a research note on Monday, December 23rd. Mizuho lowered their price objective on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a research report on Tuesday, December 10th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a research note on Friday, January 17th. Nine analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $8.39.

Revance Therapeutics Price Performance

RVNC stock opened at $3.65 on Wednesday. The business has a fifty day moving average price of $3.65 and a 200 day moving average price of $4.16. Revance Therapeutics has a fifty-two week low of $2.30 and a fifty-two week high of $6.65. The stock has a market capitalization of $381.02 million, a price-to-earnings ratio of -1.89 and a beta of 0.90.

Institutional Trading of Revance Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Intech Investment Management LLC acquired a new stake in shares of Revance Therapeutics during the 3rd quarter worth approximately $231,000. Charles Schwab Investment Management Inc. boosted its stake in Revance Therapeutics by 5.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 790,837 shares of the biopharmaceutical company’s stock valued at $4,104,000 after acquiring an additional 41,250 shares during the last quarter. Algert Global LLC grew its holdings in Revance Therapeutics by 1,167.3% during the 3rd quarter. Algert Global LLC now owns 126,730 shares of the biopharmaceutical company’s stock worth $658,000 after acquiring an additional 116,730 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in shares of Revance Therapeutics during the 3rd quarter valued at $88,000. Finally, FMR LLC lifted its stake in shares of Revance Therapeutics by 28.6% in the 3rd quarter. FMR LLC now owns 214,596 shares of the biopharmaceutical company’s stock valued at $1,114,000 after purchasing an additional 47,768 shares during the period. 97.70% of the stock is owned by institutional investors.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.